Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Recruiting now · Not applicable
Conditions studied: Long COVID, Insulin Resistance, Insulin Sensitivity
In brief
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Key facts
- Study ID
- NCT05833217
- Run by
- Stanford University
- People needed
- 55
- Starts
- 2023-06-06
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2024-12-04
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Ages 18 to 80
- BMI ≥ 25 kg/m2
- not currently pregnant
You may not qualify if…
- Arm 2 (Adipose Tissue Biopsy) exclusions include
- pregnancy
- prior liposuction
- recent change in weight (> 2 kg in one month)
- bleeding disorders
- anticoagulant use
- Arm 3 (healthy controls only) exclusions include patients with
- major organ disease
- diabetes
- history of liposuction
- bariatric surgery
- eating disorders
- psychiatric disorders
- pregnancy or lactation
- recent change in weight (over the past 12 weeks),
- use of weight loss medication or oral steroids
- hematocrit < 33%
- fasting glucose >= 126 mg/dL
- blood pressure >160/100 mmHg
Where it is running
- Stanford Health — Palo Alto, California, United States (enrolling)
- Clinical and Translational Research Unit — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.